Luchian Alina-Mihaela, Pricop M
Universitătii de Medicină şi Farmacie Gr. T. Popa, Iaşi.
Rev Med Chir Soc Med Nat Iasi. 2011 Apr-Jun;115(2):438-45.
Ovarian borderline tumors are rare, their good prognosis depending on their stage at the time of diagnosis, and the presence of invasive implants. There is little information on tumor type identified intra-surgically, as well as on the most favorable treatment in borderline ovarian tumors.
To determine the criteria of identification and presurgery and intra-surgery differentiation of the ovarian borderline tumors from the invasive carcinoma and benign ovarian tumors.
This study included 54 patients with TPMS (ovarian borderline tumors) surgically treated in the past 22 years (January 1988-December 2009) at the 4th Gynecological Clinic of the lasi "Gr. T. Popa" University of Medicine and Pharmacy. In this interval 1,107 ovarian tumors: 575 benign, 478 malignant, and 54 TPMS (4.87%) were recorded. The age of the patients with borderline tumors ranged between 20 and 78 years, mean age 46 years, and the histological types were: mucinous (27 cases), serous (18 cases), mixed (8 cases), and Brenner tumor (1 case).
We have analyzed the distribution of these cases according to the time when surgical treatment was performed. The frequency of borderline ovarian tumors in our study is 4.87%, lower than in the literature. We believe that this low percentage in our study is due to missing the microscopic data in some macroscopic benign tumors.
By this research we aimed at elaborating a therapeutic strategy for each case using with discernment the modern treatment (surgery, chemotherapy, radiotherapy), as well as new chemical drugs with the goal of obtaining better results and longer survival. There are no tumor markers which could predict the progression of a borderline ovarian tumor to invasive tumors, but the invasive course is only 0.7%.
卵巢交界性肿瘤较为罕见，其良好的预后取决于诊断时的分期以及有无浸润性种植。关于术中识别的肿瘤类型以及卵巢交界性肿瘤最适宜的治疗方法，相关信息较少。
确定卵巢交界性肿瘤与浸润性癌及卵巢良性肿瘤在术前和术中鉴别的标准。
本研究纳入了过去22年（1988年1月至2009年12月）在雅西“格·T·波帕”医药大学第四妇科诊所接受手术治疗的54例卵巢交界性肿瘤患者。在此期间共记录了1107例卵巢肿瘤，其中575例为良性，478例为恶性，54例为卵巢交界性肿瘤（4.87%）。交界性肿瘤患者年龄在20至78岁之间，平均年龄46岁，组织学类型包括：黏液性（27例）、浆液性（18例）、混合型（8例）和勃勒纳瘤（1例）。
我们根据手术治疗时间对这些病例的分布情况进行了分析。本研究中卵巢交界性肿瘤的发生率为4.87%，低于文献报道。我们认为本研究中这一低比例是由于一些宏观上为良性的肿瘤缺少微观数据所致。
通过本研究，我们旨在针对每个病例精心制定一种治疗策略，审慎运用现代治疗方法（手术、化疗、放疗）以及新型化学药物，以期获得更好的治疗效果和更长的生存期。目前尚无肿瘤标志物能够预测卵巢交界性肿瘤向浸润性肿瘤的进展，但其浸润进程仅为0.7%。
